Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Blood (2024) 144 (Supplement 1): 997.

https://doi.org/10.1182/blood-2024-201729

Published: 2024

Journal Articles

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Blood (2024) 144 (Supplement 1): 476.

https://doi.org/10.1182/blood-2024-201218

Published: 2024

Journal Articles

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2024-203274

Published: 2024

Journal Articles

Prior Azacitidine and Ongoing Transfusion Dependence in MDS Patients Are Associated with Inferior Survival after Allogeneic Stem Cell Transplant

Miles Horton, Becky Leung, Ricky Nelles, Matthew Rubic, Christopher McKinnely, Alia Cibich, Mark R Dowling, Stewart Hunt, Lynette C.Y. Chee, Ashleigh P Scott, David S. Ritchie, Devendra Hiwase, Duncan Purtill, Abir Bhattacharya, Glen A Kennedy, Ashish Bajel

Blood (2024) 144 (Supplement 1): 7440.

https://doi.org/10.1182/blood-2024-209705

Published: 2024

Journal Articles

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Blood (2024) 144 (Supplement 1): 4591.

https://doi.org/10.1182/blood-2024-208186

Published: 2024

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

Claire N Harrison, David M. Ross, Lynette C.Y. Chee, Shuhying Tan, Marielle Wondergem, Timothy Devos, Christine Graham, Allie McGinty, Michael Pace, Hongying Wang, Ying Jiang, Suresh Bobba, Katie Louise Dawson, Christopher Rovaldi, Montagu Hankin, Dena Grayson, Simon Cooper, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2023-187099

Published: 2023

Journal Articles

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Rithin Nedumannil, Tal Karmi, Piers Blombery, Charlotte Hughes, Jeff Szer, David S. Ritchie, Lynette C.Y. Chee

Blood (2023) 142 (Supplement 1): 629.

https://doi.org/10.1182/blood-2023-174666

Published: 2023

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Lower Cumulative Incidence of Relapse but Higher Incidence of NRM in Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation

Ashvind Prabahran, Rachel Koldej, Lynette C.Y. Chee, David S. Ritchie

Blood (2023) 142 (Supplement 1): 4912.

https://doi.org/10.1182/blood-2023-190941

Published: 2023

Journal Articles

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Lynette C.Y. Chee, David M. Ross, Thomas Cluzeau, Shuhying Tan, Aristoteles Giagounidis, David Valcarcel, Montserrat Arnan, Maria Diez-Campelo, Christine Graham, Allie McGinty, Miranda Ross, Suresh Bobba, Wei Feng, Ying Jiang, Montagu Hankin, Christopher Rovaldi, Simon Cooper, Dena Grayson, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 1089.

https://doi.org/10.1182/blood-2023-186326

Published: 2023

Journal Articles

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Maria Diez-Campelo, David M. Ross, Aristoteles Giagounidis, Shuhying Tan, Thomas Cluzeau, Lynette C.Y. Chee, David Valcarcel, Montserrat Arnan, Christine Graham, Allie McGinty, Miranda Ross, Wei Feng, Ying Jiang, Suresh Bobba, Montagu Hankin, Christopher Rovaldi, Dena Grayson, Simon Cooper, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 196.

https://doi.org/10.1182/blood-2023-180974

Published: 2023

Journal Articles

Immunologic Basis to Poor Graft Function Following Allogeneic Stem Cell Transplantation

Ashvind Anand Prabahran, Rachel M Koldej, Lynette C.Y. Chee, David Ritchie

Blood (2022) 140 (Supplement 1): 10453–10454.

https://doi.org/10.1182/blood-2022-167949

Published: 2022

Journal Articles

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Lynette C.Y. Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, David T Yeung, Timothy Hughes, Naranie Shanmuganathan

Blood (2022) 140 (Supplement 1): 6800–6802.

https://doi.org/10.1182/blood-2022-163221

Published: 2022

Journal Articles

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Lynette C.Y. Chee, David M Ross, Shuh Ying Tan, Joel Wight, George Kannourakis, Miranda Ross, Wei Feng, Ying Jiang, Harveen Dhillon Natarajan, Christine Graham, Christopher Rovaldi, Simon Cooper, Jen L. Salstrom

Blood (2022) 140 (Supplement 1): 8181–8183.

https://doi.org/10.1182/blood-2022-166578

Published: 2022

Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Blood (2021) 138 (Supplement 1): 310.

https://doi.org/10.1182/blood-2021-152561

Published: 2021

Journal Articles

Recurrent CMV Viremia Portends Poor Prognosis and Results in Significant Resource Utilization in Patients with Poor Graft Function Post Allogeneic Stem Cell Transplantation

Ashvind Anand Prabahran, Lynette C.Y. Chee, Rachel M Koldej, Michelle K Yong, David Ritchie

Blood (2021) 138 (Supplement 1): 4854.

https://doi.org/10.1182/blood-2021-153912

Published: 2021

Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2021-147335

Published: 2021

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

NARROW

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Prior Azacitidine and Ongoing Transfusion Dependence in MDS Patients Are Associated with Inferior Survival after Allogeneic Stem Cell Transplant

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Lower Cumulative Incidence of Relapse but Higher Incidence of NRM in Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Immunologic Basis to Poor Graft Function Following Allogeneic Stem Cell Transplantation

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Recurrent CMV Viremia Portends Poor Prognosis and Results in Significant Resource Utilization in Patients with Poor Graft Function Post Allogeneic Stem Cell Transplantation

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only